Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
Catalyst Pharmaceuticals Inc CPRX
News
-
Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
20 companies screened for quality in a cheap part of the stock market
20 companies screened for quality in a cheap -2-
20 companies screened for quality in a cheap part of the stock market
20 companies screened for quality in a cheap -2-
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
Thinking about buying stock in Praxis Precision Medicines, Safety Shot, Catalyst Pharmaceuticals, Adicet Bio, or Exscientia?
Thinking about buying stock in Analog Devices,Catalyst Pharmaceuticals, QuickLogic, Synopsys, or Pagaya Technologies?
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
Catalyst Pharmaceuticals to Commercialize Duchenne Treatment in 1Q24 After FDA Approval
